Skip Navigation


Rheumatology Advance Access originally published online on June 18, 2008
Rheumatology 2008 47(8):1168-1171; doi:10.1093/rheumatology/ken226
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/8/1168    most recent
ken226v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by van de Geijn, F. E.
Right arrow Articles by Dolhain, R. J. E. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by van de Geijn, F. E.
Right arrow Articles by Dolhain, R. J. E. M.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Mannose-binding lectin polymorphisms are not associated with rheumatoid arthritis—confirmation in two large cohorts

F. E. van de Geijn1,2, J. M. W. Hazes1, K. Geleijns3, M. Emonts4, B. C. Jacobs2,3, B. C. M. Dufour-van den Goorbergh2 and R. J. E. M. Dolhain1

1Department of Rheumatology, 2Department of Immunology, 3Department of Neurology, Erasmus MC University Medical Center Rotterdam and 4Department of Paediatrics, Erasmus MC–Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Correspondence to: F. E. van de Geijn, Department of Rheumatology, Room Ee965, Erasmus MC University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. E-mail: f.vandegeijn{at}erasmusmc.nl


  Abstract

Objectives. In RA, conflicting results have been described on the association between genotypes of the complement factor mannose-binding lectin (MBL) and disease susceptibility and severity. This might be due to underpowerment of previous research work and the fact that no confirmation cohorts were used. Therefore a different approach is warranted.

Methods.MBL2 gene polymorphisms were determined in two RA cohorts (378 and 261 cases) and 648 controls. Considering MBL polymorphisms, cases and controls were categorized in groups of high, intermediate and low MBL production. The total sample size allows detection of a potential association between RA susceptibility and MBL groups with an odds ratio of 1.37 ({alpha} < 0.05; 1–β > 0.8). Disease severity as defined by the need for anti-TNF therapy was also analysed for possible associations with MBL groups.

Results. There was no difference in the frequencies between MBL genotypes of RA cases and controls that are associated with high (cases 54.4%, controls 57.0%), intermediate (cases 28.9%, controls 27.5%) or low (cases 16.7%, controls 15.5%) MBL production. Furthermore, there was no association between MBL groups and disease severity.

Conclusions. MBL genotype groups are not associated with RA disease susceptibility or severity in this large study including a confirmation cohort. Compared with previous smaller studies these results add to more definite conclusions.

KEY WORDS: Mannose-binding lectin, Polymorphisms, Rheumatoid arthritis, Disease susceptibility, Disease severity

Submitted 14 January 2008; revised version accepted 15 May 2008.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.